Navigation Links
Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics
Date:9/15/2008

Journalists are invited to attend the 20th EORTCNCIAACR Symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland [Geneva Palexpo, Geneva] from Tuesday 21 October-Friday 24 October.

Today (Monday 15 September) is the deadline for booking accommodation via the official local agent if you wish to attend this symposium, organised jointly by the European Organisation for the Research and Treatment of Cancer, the US National Cancer Institute and the American Association for Cancer Research.

The symposium offers:

  • Cutting edge information on new cancer drug research and development from experts in Europe, North America, Asia and Australia;
  • Free registration for bona fide media with official press credentials (press card and/or a commissioning letter from the editor of the journal/website they represent);
  • All sessions open to journalists;
  • Media centre with free computing, fax, international phone, internet and photocopying facilities;
  • Two news briefings (12.15 hrs CEST: Wednesday 22 October and Thursday 23 October)

Topics at the news briefings or to be press released include:

  • Crossing the blood-brain barrier: scientists develop a new drug delivery system for hard-to-treat cancers of the central nervous system;
  • New "spindle poisoning" drug shows promise in phase I trial of solid tumours: phase II trials planned;
  • Scientists discover pattern of gene expression that predicts response to treatment in advanced colorectal cancer;
  • New drug shows impressive activity in patients with advanced disease, including medullary thyroid cancer. Phase III trials planned;
  • Researchers discover that a genetic mutation makes metastatic colorectal cancer patients resistant to anti-EGFR drugs. Potential for a biomarker to select patients who would respond to treatment;
  • Cancer vaccine shows promise in patients with bowel, kidney and prostate cancer: phase III trials on-going.

Please note: the details contained in this media alert are for information only and are embargoed until the time of the news briefings or press releases.

The symposium is an opportunity for journalists to listen and talk to some of the 2,200 European, American and other international experts in oncology gathered in Geneva to share findings on the latest research on new molecular targets, designer diagnostics and prognostics, smart drugs and other novel approaches to cancer treatment.

NB: the official language of the symposium is English and all press materials will be in English.

Journalists should register to attend the symposium by downloading a registration form at: http://www.ecco-org.eu/ or by contacting Riitta Kettunen:
Email: Riitta.Kettunen@ecco-org.eu
Tel: +32 2 775 02 05
Fax: +32 2 775 02 00

More information on the programme and hotel accommodation is available on the EORTC-NCI-AACR symposium website at: http://www.ecco-org.eu/

Accommodation

This should be booked through Symporg SA, the official local agent for the symposium, via the symposium website. Symporg, SA
Tel: +41-22 839 84 84
Fax: +41-22 839 84 85
Email: info@symporg.ch

NB: the deadline for hotel reservations is September 15. Reservations are made on a first-come, first served basis and you are advised to book early.


'/>"/>

Contact: Emma Mason
wordmason@mac.com
44-077-112-96986
ECCO-the European CanCer Organisation
Source:Eurekalert

Related biology news :

1. September Geology and GSA Today media highlights
2. Heart of Herschel to be presented to media
3. Last chance for media to register for ECCO 14 -- the European Cancer Conference
4. October Geology and GSA Today media highlights
5. Media highlights in the November issues of Biophysical Journal
6. November GEOLOGY and GSA TODAY Media Highlights
7. Nanotechnology and the media: The inside story
8. December GEOLOGY and GSA TODAY media highlights
9. Better protection for biomedial devices could result from Rutgers-Camden research
10. Media highlights in the Dec. 15 issue of Biophysical Journal
11. Immediate action needed to save corals from climate change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2017)... Calif. , Jan. 5, 2017  Delta ID ... its iris scanning technology for automotive at CES® 2017. ... GNTX ) to demonstrate the use of iris ... identify and authenticate the driver in a car, and ... during the driving experience. Delta ID and ...
(Date:12/22/2016)... -- As part of its longstanding mission to improve genetic literacy ... released its latest children,s book, titled The One ... topics of inheritance and variation of traits that are part ... school classrooms in the US. The book ... Killoran , whose previous book with 23andMe, You ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... HOUSTON , Jan. 19, 2017 ... announced the formation of its Medical/Clinical Advisory Board. ... industry veterans who enhance the range and depth ... development of its novel prenatal diagnostic tests.  These ... and strategic guidance for the company,s product development ...
(Date:1/19/2017)... Research and Markets ... has announced the addition of the ... 2025" report to their offering. Report ... provides a detailed analysis on current and future market trends to identify ... market values as the base numbers Key market trends ...
(Date:1/19/2017)... ... January 19, 2017 , ... November Research Group, LLC, ... and medical device manufacturers and regulators, is proud to announce the worldwide release ... client designed to provide product vigilance departments with the flexibility and ease of ...
(Date:1/19/2017)... 19, 2017  ArmaGen, Inc., today announced that ... as chief executive officer, as well as a ... to ArmaGen more than 17 years of executive ... of biotherapeutics and pharmaceuticals. "Mathias ... experience and skillset necessary to lead ArmaGen to ...
Breaking Biology Technology: